Bachem Holding AG (BANB) AI Stock Analysis

• Market Cap: CHF4.68B
• Dividend Yield: 1.33%
• Average Volume (3M): 69.38K
• Price to Earnings (P/E): 34.9
• Beta (1Y): 1.20
• Revenue Growth: 17.34%
• EPS Growth: 18.15%
• Country: CH
• Employees: 2,207
• Sector: Healthcare
• Sector Strength: 45
• Industry: Chemicals
• EPS (TTM): 0.67
• Shares Outstanding: 75,000,000
• 10 Day Avg. Volume: 66,251
• 30 Day Avg. Volume: 69,382
• PEG Ratio: 5.42
• Price to Book (P/B): 3.12
• Price to Sales (P/S): 7.17
• P/FCF Ratio: -31.39
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF78.17
• Price Target Upside: 22.05% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 68 Neutral
• Price Target: CHF69.00 ▲(7.73% Upside)

Bachem Holding AG's strong financial performance is the most significant factor, supported by robust revenue growth and a solid balance sheet. However, technical indicators suggest potential short-term weakness, and the valuation appears slightly high, which tempers the overall score.

Bachem Holding AG Business Overview & Revenue Model

Company Description

Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.

How the Company Makes Money

Bachem generates revenue primarily through the sale of its peptide and oligonucleotide products, which are utilized by pharmaceutical companies in drug development and production. The company's revenue model is based on long-term contracts with clients for custom synthesis services, as well as the sale of standard peptide products. Key revenue streams include bulk sales of therapeutic peptides, contract manufacturing services, and royalties from patented products. Significant partnerships with major pharmaceutical firms enhance its market position and contribute to its earnings, as these collaborations often lead to large-scale production agreements and increased demand for Bachem's innovative solutions.

Bachem Holding AG Financial Statement Overview

Summary

Bachem Holding AG demonstrates strong financial performance with consistent revenue growth, stable gross profit margins, and healthy net profit margins. The balance sheet is robust with low leverage and a strong equity base, while cash flow management is effective despite recent negative free cash flow due to strategic capital expenditures.

Income Statement

Bachem Holding AG has shown a strong revenue growth rate with revenues increasing consistently year over year. The gross profit margin is stable, indicating good control over production costs. Net profit margins are healthy, supported by increasing net income over the past few years. EBIT and EBITDA margins are strong, showcasing efficient operations. The company has demonstrated solid growth and profitability in the medical pharmaceuticals sector.

Balance Sheet

The company maintains a low debt-to-equity ratio, reflecting low leverage and financial stability. The return on equity is robust, indicating effective use of equity to generate profits. The equity ratio is high, underscoring a strong capital structure. Bachem has increased its total assets significantly, primarily funded by equity, which reduces potential risks associated with high leverage.

Cash Flow

Bachem Holding AG exhibits strong operating cash flow relative to net income, indicating effective cash generation from operations. However, the free cash flow has been negative recently due to high capital expenditures, which could limit liquidity in the short term. Despite this, the company's investment in growth seems to be strategically driven.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	677.93M	605.26M	577.32M	531.74M	503.23M	402.00M
Gross Profit	211.69M	182.56M	176.96M	171.28M	166.73M	128.91M
EBITDA	190.52M	178.76M	163.28M	157.08M	156.47M	121.72M
Net Income	134.19M	120.25M	111.86M	100.68M	114.68M	78.06M
Balance Sheet
Total Assets	1.91B	1.92B	1.68B	1.38B	1.30B	710.88M
Cash, Cash Equivalents and Short-Term Investments	29.14M	95.20M	298.53M	268.43M	442.36M	23.50M
Total Debt	60.87M	290.00K	401.00K	691.00K	20.86M	107.55M
Total Liabilities	550.82M	531.88M	362.36M	214.21M	177.50M	235.17M
Stockholders Equity	1.36B	1.39B	1.32B	1.17B	1.12B	475.71M
Cash Flow
Free Cash Flow	-118.94M	-138.30M	-18.54M	-49.76M	-19.66M	45.53M
Operating Cash Flow	144.66M	146.32M	249.86M	92.59M	97.16M	114.63M
Investing Cash Flow	-172.39M	-148.88M	-170.81M	-63.17M	-469.13M	-69.31M
Financing Cash Flow	-5.30M	-61.26M	48.69M	-86.93M	437.58M	-42.66M

Bachem Holding AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 64.05
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:BANB, the sentiment is Positive. The current price of 64.05 is above the 20-day moving average (MA) of 63.75, below the 50-day MA of 64.36, and above the 200-day MA of 57.24, indicating a neutral trend. The MACD of -0.63 indicates Positive momentum. The RSI at 51.00 is Neutral, neither overbought nor oversold. The STOCH value of 56.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:BANB.

Bachem Holding AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GALE	71 Outperform	4.27B	22.24	11.81%	2.68%	5.84%	8.57%
LONN	69 Neutral	37.29B	51.79	6.82%	0.73%	5.93%	29.83%
BANB	68 Neutral	CHF4.68B	34.89	10.07%	1.33%	17.34%	18.15%
YPSN	66 Neutral	5.67B	64.10	12.87%	0.53%	36.54%	11.60%
SFZN	66 Neutral	3.90B	24.37	16.33%	0.44%	0.77%	16.70%
PPGN	60 Neutral	855.51M	-26.12	-5.48%	―	12.03%	-19.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Bachem Holding AG Corporate Events

Bachem Appoints Hans Van Hees as New COO to Strengthen Global Operations

Bachem Holding AG has announced the appointment of Hans Van Hees as the new Chief Operations Officer (COO) and member of the Executive Committee, effective September 1, 2025. This strategic move aims to enhance Bachem’s global production network, following significant progress in its operations and capacity expansions under CEO Thomas Meier’s interim leadership as COO. Hans Van Hees brings extensive experience from his previous roles at Johnson & Johnson and Janssen, which is expected to further strengthen Bachem’s industry positioning.

The most recent analyst rating on (CH:BANB) stock is a Buy with a CHF77.00 price target. To see the full list of analyst forecasts on Bachem Holding AG stock, see the CH:BANB Stock Forecast page.

Bachem Reports Robust Growth and Expansion Plans for 2025

Bachem Holding AG reported a strong financial performance in the first half of 2025, with group sales reaching CHF 313.0 million, marking a 30.2% increase compared to the previous year. The company also saw a significant rise in EBITDA to CHF 91.0 million, reflecting a 64.0% increase. Bachem is investing heavily in expanding its production capacity, with more than CHF 400 million planned for 2025, and aims for over CHF 1 billion in revenue by 2026. The expansion includes the development of a new production site in Sisslerfeld, Switzerland, and the continued enhancement of existing facilities. These strategic moves are expected to bolster Bachem’s market position and meet the growing demand for its products.

The most recent analyst rating on (CH:BANB) stock is a Buy with a CHF100.00 price target. To see the full list of analyst forecasts on Bachem Holding AG stock, see the CH:BANB Stock Forecast page.